Viyash Scientific Q1 FY27: PAT up 115% to ₹793m

Overview: profit more than doubles in Q1 FY27

Viyash Scientific Limited reported a sharp jump in profitability for the quarter ended June 30, 2026 (Q1 FY27), supported by steady revenue growth and a meaningful expansion in operating margins. Consolidated profit after tax (PAT) rose to ₹793 million, a 114.9% year-on-year (YoY) increase. Revenue from operations increased 19.5% YoY to ₹9,464 million, while consolidated EBITDA (excluding ESOP costs) grew 59.2% YoY to ₹2,047 million.

The quarter was also marked by an improvement in balance sheet leverage, with net debt reducing to ₹860 million. Management highlighted that net debt-to-EBITDA improved to 0.1x from 1x a year ago, indicating a substantially lower finance burden and greater financial flexibility.

Key Q1 FY27 headline numbers

On the top line, Viyash Scientific recorded consolidated revenue from operations of ₹9,464 million versus ₹7,916 million in Q1 FY26, translating into 19.5% YoY growth. Operating performance improved faster than revenue, as EBITDA expanded at a much stronger pace than sales. PAT more than doubled to ₹793 million from ₹369 million in Q1 FY26.

The company also disclosed standalone PAT of ₹209 million for Q1 FY27. However, standalone gross margin and standalone EBITDA were not broken out in the extract provided, limiting like-for-like margin comparison at the standalone level.

Margin expansion drove the outsized earnings growth

A key feature of the quarter was the scale of margin expansion. EBITDA margin (excluding ESOP costs) improved to 21.6% in Q1 FY27 from 16.2% in Q1 FY26, an improvement of 530 basis points. This step-up in margin translated into a 59.2% YoY rise in EBITDA to ₹2,047 million, materially ahead of the 19.5% increase in revenue.

Gross margin also improved. In absolute terms, gross margin increased to ₹5,121 million from ₹4,111 million in Q1 FY26. Gross margin as a percentage of revenue moved up to 54.1% from 51.9% a year earlier, indicating a better mix and or improved cost performance during the quarter.

Profitability: PAT at ₹793 million, EBT more than doubles

The profitability improvement was visible across the income statement. Earnings before tax (EBT) for Q1 FY27 stood at ₹1,124 million, up from ₹483 million in Q1 FY26. PAT increased to ₹793 million, reinforcing that the margin expansion was substantial enough to deliver a disproportionate rise in net earnings compared with revenue growth.

Management also linked the PAT jump to strong operational performance and lower finance costs. The reduction in net debt and the sharp fall in leverage ratio are consistent with that narrative, though the extract does not provide an interest expense line item.

Net debt reduced to ₹860 million

Viyash Scientific reported net debt of ₹860 million for Q1 FY27, and described the company as “virtually debt-free” in the earnings summary. The company also stated that net debt-to-EBITDA improved to 0.1x from 1x a year ago.

From an investor lens, the combination of higher EBITDA and lower net debt typically strengthens capacity for planned capital expenditure and other strategic moves. In the call summary, management indicated that the balance sheet position supports brownfield expansion and inorganic opportunities.

Consolidated vs standalone: what is disclosed

The extract provides both consolidated and standalone figures for selected lines. Consolidated revenue from operations was ₹9,464 million in Q1 FY27, while standalone revenue from operations was ₹3,537 million. Consolidated PAT was ₹793 million, while standalone PAT was ₹209 million.

However, the document explicitly notes that standalone gross margin and standalone EBITDA were not provided in the extract, so the operating profitability comparison in this article is focused on consolidated performance.

What management highlighted on the earnings call

In the Q1 FY27 earnings call summary, Dr. Hari Babu, Managing Director and Group CEO, highlighted three core points: revenue from operations grew to ₹9,464 million (INR 946 crores), EBITDA rose to ₹2,047 million (INR 205 crores) with margin expansion to 21.6%, and PAT increased to ₹793 million (INR 79 crores).

The same summary also stated that net debt reduced to ₹860 million (INR 86 crores), bringing net debt-to-EBITDA down to 0.1x from 1x a year ago. Management linked the improved profitability to operational performance and lower finance costs.

Results date and earnings call details

The company cited August 11, 2026 as the results date, with an earnings call scheduled for August 12, 2026 at 3:30 PM IST. Participants were provided dial-in numbers (+91 22 6280 1263 and +91 22 7115 8213) and a reference to early registration through a “Diamond Pass” link on the investor relations portal.

The earnings call transcript was expected to be available in a week’s time on the company’s website, according to the call notes included in the extract.

Market impact: what the numbers change for investors

The Q1 FY27 print shows a clear operating leverage outcome: revenue grew ~20% YoY, but EBITDA rose 59.2% and PAT rose 114.9%. The margin expansion of 530 basis points to 21.6% is the single biggest quantitative indicator explaining why earnings moved faster than the top line.

Balance sheet movement adds another angle. Net debt at ₹860 million and net debt-to-EBITDA at 0.1x suggest that finance costs could be structurally lower than the previous year, aligning with management’s comment that lower finance costs supported the PAT improvement.

Key financial snapshot (consolidated)

Timeline and disclosures

Conclusion

Viyash Scientific’s Q1 FY27 results combined ~20% revenue growth with a step-up in margins, lifting consolidated EBITDA to ₹2,047 million and PAT to ₹793 million. The company also reported net debt of ₹860 million and a net debt-to-EBITDA ratio of 0.1x, materially lower than the prior year.

Next, investor focus is likely to remain on management’s discussion from the August 12, 2026 earnings call, including commentary on brownfield expansion and any inorganic opportunities referenced in the call summary.